In an adult with chronic mechanical back pain and no significant hepatic, renal, or cardiovascular disease, which muscle relaxant—tizanidine or baclofen—is preferred as initial therapy?

Tizanidine vs Baclofen for Chronic Back Pain

Tizanidine is the preferred initial muscle relaxant for chronic mechanical back pain in adults, based on superior evidence for efficacy in low back pain and a more favorable safety profile compared to baclofen.

Evidence-Based Rationale

Efficacy Considerations

Tizanidine has been well-studied specifically for low back pain, while baclofen has minimal supporting evidence for this indication. The American College of Physicians/American Pain Society guidelines explicitly state that "the antispasticity drug tizanidine has been well studied for low back pain, there is little evidence for the efficacy of baclofen or dantrolene, the other FDA-approved drugs for the treatment of spasticity" 1. This fundamental difference in the evidence base makes tizanidine the more rational choice when muscle relaxant therapy is indicated.

• A systematic review confirmed fair evidence that tizanidine is effective compared to placebo in patients with musculoskeletal conditions, primarily acute back or neck pain 2
• Clinical experience demonstrates that tizanidine provides quick pain relief in back pain accompanied by muscle spasm, with initial relief by day 2 and complete relief by day 4 of treatment 3
• The effective dose is typically low (2-4 mg three times daily), and the medication is generally well-tolerated with adverse effects occurring in less than 6% of patients 3

Safety Profile Comparison

Baclofen carries significantly higher risks of serious adverse events compared to tizanidine in older adults, which is relevant given that chronic back pain commonly affects this population. Recent high-quality comparative safety data strongly favor tizanidine:

• Baclofen is associated with a 54% increased risk of injury (HR 1.54,95% CI 1.21-1.96) and a 233% increased risk of delirium (HR 3.33,95% CI 2.11-5.26) compared to tizanidine in older adults with musculoskeletal pain 4
• A 2025 retrospective cohort study found baclofen demonstrated 69% greater risk of composite injury outcomes (aHR 1.69,95% CI 1.51-1.88) while tizanidine carried only 34% greater risk (aHR 1.34,95% CI 1.11-1.62) when compared to cyclobenzaprine 5
• Baclofen is associated with increased hospitalizations for encephalopathy, particularly in patients with chronic kidney disease (7.2% vs 0.1%) and end-stage renal disease 6
• Tizanidine has lower incidences of adverse events including injury, delirium, encephalopathy, falls, and opioid overdose compared to baclofen 7

Hepatotoxicity Considerations

Both medications carry hepatotoxicity warnings, but the clinical significance differs. The ACP/APS guidelines note that "both tizanidine and chlorzoxazone are associated with hepatotoxicity that is generally reversible and usually not serious" 1. This is in contrast to dantrolene, which carries a black box warning for potentially fatal hepatotoxicity 1.

• Monitor liver function tests periodically with either agent
• Tizanidine's hepatotoxicity is typically reversible and not serious 1
• The FDA label for tizanidine notes dose-related concerns but does not include a black box warning 8

Clinical Application Algorithm

When to Consider Muscle Relaxants

Muscle relaxants should only be considered after first-line therapies have been attempted:

1. First-line therapy: Acetaminophen or NSAIDs (if no contraindications) 1
2. If inadequate response: Consider adding tizanidine for short-term relief 1
3. Duration: Use time-limited courses; extended use should be reserved for patients showing continued benefits without major adverse events 1

Dosing Strategy

For tizanidine:

• Start at 2 mg up to three times daily 9
• Titrate slowly based on response and tolerability
• Monitor for muscle weakness, urinary function, cognitive effects, sedation, and orthostasis 9
• Typical effective dose range is low (2-4 mg three times daily) 3

For baclofen (if tizanidine is contraindicated):

• Start at 5 mg up to three times daily 9
• Older adults rarely tolerate doses greater than 30-40 mg per day 9
• Monitor muscle weakness, urinary function, cognitive effects, and sedation 9
• Avoid abrupt discontinuation due to risk of CNS irritability 9

Important Caveats and Pitfalls

Common Pitfalls to Avoid

1. Do not assume muscle relaxants are first-line therapy: The guidelines clearly position them as options for patients who have not responded adequately to acetaminophen or NSAIDs 1

2. Recognize limited long-term efficacy data: Most medication trials for low back pain were short-term, and evidence is limited on benefits and risks of long-term use 1

3. Be aware of the 2018 randomized trial showing no benefit: A well-designed ED study found that adding baclofen, metaxalone, or tizanidine to ibuprofen did not improve functioning or pain more than placebo plus ibuprofen at 1 week 10. This suggests muscle relaxants may add little value when combined with adequate NSAID therapy.

Special Populations

Women taking oral contraceptives:

• Tizanidine clearance is reduced by approximately 50% 8
• Reduce individual doses during titration rather than frequency 8

Renal impairment:

• Tizanidine clearance is reduced by more than 50% when creatinine clearance <25 mL/min 8
• Baclofen poses significant encephalopathy risk in chronic kidney disease 6
• If muscle relaxant is necessary in renal impairment, tizanidine with dose reduction is safer than baclofen

Cardiovascular disease:

• Both agents can cause hypotension and bradycardia 8, 11
• Tizanidine specifically associated with orthostatic hypotension risk 8
• Monitor blood pressure and heart rate, especially during titration

CNS Depression and Sedation

Both medications cause sedation, which is additive with other CNS depressants:

• Warn patients about performing activities requiring alertness (driving, operating machinery) 8, 11
• Avoid concurrent use with alcohol, benzodiazepines, or opioids when possible 8
• The FDA label for tizanidine specifically notes that sedation may be additive with baclofen and benzodiazepines 8

Discontinuation

Never stop either medication abruptly, especially after prolonged use:

• Risk of rebound hypertension, tachycardia, and hypertonia with tizanidine 8
• Risk of CNS irritability with baclofen 9, 11
• Taper dose slowly when discontinuing 8